Amundi Has $1.23 Billion Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Amundi reduced its Gilead Sciences stake by 7.3% in the second quarter, selling 766,673 shares but still holding 9.77 million shares worth approximately $1.23 billion. Institutional investors and hedge funds collectively own 83.67% of Gilead.
• New HIV and oncology approvals are expanding Gilead’s growth opportunities. FDA approval of Bixlenvo and European approval of Trodelvy with Keytruda could strengthen the company’s HIV and cancer franchises, while an Arcus-backed cancer trial provides another potential catalyst.
• Gilead offers a 2.2% dividend yield but faces concentration risks. The company’s $0.82 quarterly dividend is supported largely by its HIV business, which remains exposed to future patent expirations; analysts nevertheless maintain a “Moderate Buy” consensus with an average price target of $158.04.

Amundi cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,772,438 shares of the biopharmaceutical company's stock after selling 766,673 shares during the quarter. Amundi owned about 0.79% of Gilead Sciences worth $1,234,650,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GILD. HighTower Advisors LLC increased its holdings in shares of Gilead Sciences by 5.8% during the 2nd quarter. HighTower Advisors LLC now owns 1,534,627 shares of the biopharmaceutical company's stock worth $193,885,000 after acquiring an additional 84,450 shares during the last quarter. Groupe la Francaise lifted its holdings in Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company's stock valued at $6,270,000 after purchasing an additional 11,712 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Gilead Sciences during the second quarter worth $130,420,000. California State Teachers Retirement System boosted its position in Gilead Sciences by 12,498.3% during the second quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company's stock worth $30,469,248,000 after purchasing an additional 239,254,365 shares during the period. Finally, Kintra Wealth LLC increased its holdings in shares of Gilead Sciences by 11.1% in the second quarter. Kintra Wealth LLC now owns 1,989 shares of the biopharmaceutical company's stock valued at $275,000 after purchasing an additional 198 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $150.99 on Monday. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The company's 50 day moving average price is $136.67 and its two-hundred day moving average price is $136.39. The firm has a market cap of $187.22 billion, a PE ratio of -56.55 and a beta of 0.33. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Insiders Place Their Bets

In related news, CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the sale, the chief financial officer owned 165,646 shares of the company's stock, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 15,000 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $14,495,820 over the last 90 days. 0.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of Gilead Sciences from a "buy" rating to a "hold" rating in a report on Saturday. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a research note on Wednesday, August 5th. Truist Financial lowered their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a report on Tuesday, July 7th. Finally, HSBC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source